Lepu Biopharma (HKG:2157) completed a filing with the China Securities Regulatory Commission for the conversion of its 54,268,364 unlisted domestic shares and their issuance as H shares on the Hong Kong bourse, according to a Wednesday filing with the exchange.
Shares in the biopharmaceutical company rose 2% during morning trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.